Clinical trials: Castration-Resistant Prostatic Cancer
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Trial name
- NCT03822845
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Graham PhD, MD
Metastatic Castration Resistant Prostate Cancer
A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone
The purpose of the study was to understand if there was benefit in continued treatment with a medicine called enzalutamide, when starting treatment with docetaxel and prednisolone (a standard chemotherapy for prostate cancer)…
- Trial name
- PRESIDE (NCT02288247)
- Testing
- Enzalutamide, Docetaxel, Prednisolone
- Where
- 89 sites in Austria, Belgium and 14 more
- Volunteers
- 688 people
- Sponsor
- Astellas Pharma Europe Ltd.
Metastatic Castration-resistant Prostate Cancer
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Trial name
- NCT04556617
- Testing
- PLX2853 20 mg, Olaparib, Abiraterone acetate
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Opna Bio LLC
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating persons with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03805594
- Testing
- Lutetium Lu 177-PSMA-617, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
Prostate Cancer, Castration-resistant Prostate Cancer
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
This is a study to evaluate the safety and clinical activity of the combination of olaparib and high-dose IV ascorbate, as second or later line of therapy, in castration resistant prostate cancer patients with no known DNA repair…
- Trial name
- NCT05501548
- Testing
- Olaparib, Vitamin C
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Castration-resistant Prostate Cancer
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
A first-in-human clinical trial to test the investigational treatment ONCT-534 in participants with metastatic castration-resistant prostate cancer.
- Trial name
- NCT05917470
- Testing
- ONCT-534
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 21 people
- Sponsor
- Oncternal Therapeutics, Inc
Castration-Resistant Prostate Cancer (CRPC)
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
- Trial name
- NCT01534052
- Testing
- Enzalutamide
- Where
- 7 sites in United States, Moldova and 1 more
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
This is a multicenter phase 2 open label study of pembrolizumab in patients with metastatic castrate resistant prostate cancer (mCRPC) with or without DNA damage repair defects.
- Trial name
- NCT03248570
- Testing
- Pembrolizumab, Chemotherapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Francisco
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
This phase II trial studies the safety, tolerability and how well durvalumab and tremelimumab work in treating participants with castration-resistant prostate cancer who have not received chemotherapy (chemotherapy naïve) and has…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT03204812
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Prostatic Neoplasms, Castration-Resistant
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study will be a retrospective data analysis to compare outcomes between patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated enzalutamide and those who initiated abiraterone…
- Trial name
- NCT05520138
- Testing
- Enzalutamide, Abiraterone acetate
- Where
- United States
- Volunteers
- 5,506 people
- Sponsor
- Pfizer
Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
This phase II trial studies genetic and molecular mechanisms in assessing response in patients with prostate cancer receiving enzalutamide therapy. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Adenocarcinoma
- Trial name
- NCT02099864
- Testing
- Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- OHSU Knight Cancer Institute
Prostatic Neoplasms, Castration-Resistant
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in combination with enzalutamide compared with enzalutamide…
- Trial name
- IMbassador250 (NCT03016312)
- Testing
- Atezolizumab, Enzalutamide
- Where
- 158 sites in United States, Australia and 19 more
- Volunteers
- 759 people
- Sponsor
- Hoffmann-La Roche
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
This phase II trial studies the side effects of ESK981 and nivolumab and to see how well they work for the treatment of castration resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT04159896
- Testing
- Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer, Prostatic Neoplasm
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new prostate-specific membrane antigen (PSMA) drug makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Cancer Recurrent
- Trial name
- NCT03389451
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Michael Graham PhD, MD
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CATCH-R (NCT04676334)
- Testing
- Rucaparib
- Where
- 25 sites in Canada, Israel and 4 more
- Volunteers
- 34 people
- Sponsor
- pharmaand GmbH
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
This is an open-label Phase II modular study in participants with prostate cancer which will assess safety, efficacy, and tolerability of AZD4635 in combination with other therapeutic agents in different treatment arms (referred…
- Trial name
- NCT04089553
- Testing
- AZD4635, Oleclumab, Durvalumab
- Where
- 9 sites in United States
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
COMbination of Bipolar Androgen Therapy and Nivolumab
Single arm, multicenter, open-label Phase II study of the effects of parenteral testosterone in combination with nivolumab in men with metastatic castration-resistant prostate cancer who previously progressed on at least one…
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
- Trial name
- COMBAT-CRPC (NCT03554317)
- Testing
- Testosterone cypionate, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Prostatic Neoplasm
68Ga PSMA in Preprostatectomy Patients
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasm of Uncertain Behavior
- Trial name
- NCT03388346
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Michael Graham PhD, MD
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
- Trial name
- NCT04887506
- Testing
- TAVT-45, Zytiga, Prednisone
- Where
- 42 sites in United States, France and 6 more
- Volunteers
- 107 people
- Sponsor
- Tavanta Therapeutics
Metastatic Castration-resistant Prostate Cancer
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
This is a 2-part study in patients with metastatic CRPC. Part A is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once…
- Trial name
- NCT01972217
- Testing
- Olaparib, Abiraterone, Prednisone or prednisolone
- Where
- 41 sites in United States, Belgium and 9 more
- Volunteers
- 158 people
- Sponsor
- AstraZeneca